# OnCo record lymphoma-tx-crs-icans (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/lymphoma-tx-crs-icans/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "lymphoma-tx-crs-icans" ;
  schema:name "Cytokine release syndrome and ICANS: grading and management"@en ;
  schema:alternateName "CRS grading"@en, "ASTCT consensus grading"@en, "Immune effector cell-associated neurotoxicity syndrome"@en, "Tocilizumab for CRS"@en, "ICE score"@en ;
  schema:description "When engineered T cells or a bispecific antibody switch on, the immune system can overshoot. The first sign is a fever, and the treatment is a drug that blocks the main signal, given early. A smaller number of people become confused or drowsy, which is graded and treated separately."@en ;
  schema:url <https://onco.cc/terms/lymphoma-tx-crs-icans/> ;
  schema:dateModified "2026-09-29"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.bbmt.2018.12.758> ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:drugs <https://onco.cc/drugs/tocilizumab/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/drugs/brexucabtagene-autoleucel/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/mosunetuzumab/>, <https://onco.cc/drugs/odronextamab/> ;
  onco:terms <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/>, <https://onco.cc/terms/lymphodepletion/> ;
  onco:trials <https://onco.cc/trials/zuma-1/>, <https://onco.cc/trials/zuma-2/>, <https://onco.cc/trials/zuma-5/>, <https://onco.cc/trials/transform/> .